Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.58 |
| ▸ | P2RX7 | Q99572 | 15/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8880131 | 0.83 | ITGB3 (0.56) | ITGB3ITGA2BP2RX7 | |
| SCHEMBL8880135 | 0.83 | ITGB3 (0.56) | ITGB3ITGA2BP2RX7 | |
| SCHEMBL8880972 | 0.82 | ITGB3 (0.60) | ITGB3ITGA2BP2RX7 | |
| SCHEMBL8519246 | 0.81 | ITGB3 (0.67) | ITGB3ITGA2BP2RX7 | |
| SCHEMBL8880919 | 0.80 | ITGB3 (0.54) | ITGB3ITGA2BP2RX7 | |
| SCHEMBL8690019 | 0.80 | HRH2 (0.52) | ITGB3ITGA2BP2RX7 | |
| SCHEMBL7308440 | 0.76 | ITGB3 (0.70) | ITGB3ITGA2B | |
| SCHEMBL8882218 | 0.75 | KMT2A (0.47) | ITGB3ITGA2BP2RX7 | |
| SCHEMBL8816136 | 0.75 | FPR2 (0.62) | P2RX7 | |
| SCHEMBL8816132 | 0.75 | FPR2 (0.62) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
| EP-1677783-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | Nicholas Piramal India Limited (IN) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005035495-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | FGB, F13B, F2 | ITGB3 169/4885ITGA2B 63/4885P2RX7 468/4885 |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | FGB, F13B, F2 | ITGB3 169/4885ITGA2B 63/4885P2RX7 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.